Harm reduction and the role of novel nicotine-delivery products in smoking cessation and tobacco control

Harm reduction and the role of novel nicotine-delivery products in smoking cessation and tobacco control - hero image

This module will review harm reduction and the role of novel nicotine-delivery products in smoking cessation and tobacco control.

Tobacco use remains a major health issue, although tobacco control policies have led to a decline in smoking in most European countries in recent decades. However, the landscape is constantly changing and novel products such as electronic nicotine delivery systems or ENDS (e-cigarettes) and heated tobacco products are becoming increasingly popular.

These products have generated a discussion about harm reduction, which is largely, but not exclusively driven by the tobacco industry, which is promoting ENDS and HTP as less harmful alternatives to smoking. This is not the first time we see this. The tobacco industry has a long history of promoting products that were supposed to be safer, such as filtered or light cigarettes.

The reality is that there is a heated debate around novel nicotine products that has divided the health community. In this module we will talk about why it is important to discuss harm reduction and what is meant by harm reduction applied to tobacco control; and debate the evidence-based arguments of the ERS position paper on tobacco harm reduction.

Access the full module

CME Online

More content like this

Access the CME Online archive to watch past modules.

Visit the archive